Voyager Therapeutics (VYGR) Non-Current Deffered Revenue (2014 - 2025)

Voyager Therapeutics (VYGR) has 12 years of Non-Current Deffered Revenue data on file, last reported at $1.5 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 87.9% year-over-year to $1.5 million; the trailing twelve-month figure through Sep 2025 stood at $1.5 million (down 87.9% YoY), and the FY2024 full-year result was $6.0 million, down 81.45% from the prior year.
• Non-Current Deffered Revenue slipped to $1.5 million in Q3 2025, from $2.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $78.9 million in Q1 2023 to a low of $1.5 million in Q3 2025.
• A 5-year average of $20.7 million and a median of $12.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue soared 833.51% in 2023 and plunged 87.9% in 2025, its largest moves.
• Tracing VYGR's Non-Current Deffered Revenue over 5 years: stood at $8.2 million in 2021, then retreated by 21.44% to $6.4 million in 2022, then soared by 401.69% to $32.4 million in 2023, then plunged by 81.45% to $6.0 million in 2024, then sank by 75.5% to $1.5 million in 2025.
• Business Quant data shows VYGR's Non-Current Deffered Revenue at $1.5 million in Q3 2025, $2.6 million in Q2 2025, and $4.8 million in Q1 2025.